While our study primarily focuses on mCRC, these preliminary findings suggest that the role of PRTN3 in angiogenesis and the chemotherapy response may extent to the patients with stage I-III CRC, other cancer types, and other drugs targeting vascularization. This evidence concerns the gene PRTN3 and cancer.